effects [qlco]
Six [qnco]
months [tmco]
treatment [ftcn]
Low dose [qnco]
Conjugated [spco]
Oestrogens [horm, phsu, strd]
Menopausal [phsf]
Women [popg]
Objective [inpr]
Hormone replacement therapy [topp]
prescribed [hlca]
Medium [inpr]
High dose [qnco]
Formulation [resa]
Little NOS [cgab, dsyn]
Known [qlco]
Dose-dependent [qnco]
Estrogen Effect [fndg]
Plasma [bdsu]
hormone levels [lbtr]
Marker [clna]
CARDIOVASCULAR [bdsy]
Lipid Metabolism [moft]
haemostatic [ortf]
System [ftcn]
Marker [clna]
Bone [bpoc]
turnover [qnco]
Subject [grup]
Design [acty]
Open [spco]
Trial [resa]
Group [idcn]
Health [idcn]
Obese [dsyn]
postmenopausal [tmco]
Women [popg]
Received [qlco]
Conjugated oestrogens [horm, phsu, strd]
Equine [mamm]
cee [orch]
months [tmco]
Doses [qnco]
mg day [qnco]
Group 1 [inpr]
mg day [qnco]
Group 2 [inpr]
1 Day [tmco]
mg% [qnco]
Group 3 [inpr]
cee [orch]
Administered [ftcn]
Alone [qnco]
Ii [aapp]
Combination [qlco]
mg% [qnco]
Medrogestone [horm, phsu, strd]
treatment [ftcn]
Cycle [tmco]
pause [tmco]
7 days [tmco]
Fasting [fndg]
Blood sample [bdsu]
Obtained [ftcn]
treatment [ftcn]
days [tmco]
Sixth [qnco]
months [tmco]
treatment [ftcn]
Obtained [ftcn]
Grouped [spco]
Together [qlco]
Phase [tmco]
Phase [tmco]
Phase [tmco]
measurements [ftcn]
plasma concentration [qnco]
Estradiol [horm, phsu, strd]
Dehydroepiandrosterone Sulfate [bacs, phsu, strd]
Total testosterone [horm, phsu, strd]
PRL [gngm]
Sex Hormone-Binding Globulin [aapp, bacs]
Type 1 [clas]
Procollagen [aapp, bacs]
Propeptide [aapp]
Cross Linked [npop]
Type 1 Collagen [aapp, bacs]
Total Cholesterol [lbpr]
Cholesterol, HDL [bacs, lipd]
Triglycerides [bacs, lipd]
Apolipoprotein A-1 [aapp, bacs]
Apolipoprotein B [aapp, bacs]
Lipoprotein (a) [aapp, bacs]
Lp(a) [aapp, bacs]
Fibrinogen [aapp, bacs, phsu]
Plasminogen Activator Inhibitor 1 [aapp, bacs]
Evaluated [ftcn]
Available [ftcn]
Kits [qlco]
Dose [qnco]
regimens [inpr]
Increased [qnco]
Sex Hormone-Binding Globulin [aapp, bacs]
activity [dora]
decreased fsh [fndg]
dheas [horm, phsu, strd]
Cholesterol [bacs, strd]
Cholesterol, LDL [bacs, strd]
Apo-B [aapp, bacs]
Cholesterol, HDL [bacs, lipd]
Apo A-1 [aapp, bacs]
Slightly [idcn]
Decreased [qnco]
Group 1 [inpr]
Increased [qnco]
Group 2 [inpr]
cee [orch]
Dosage [qnco]
Group 3 [inpr]
Triglycerides [bacs, lipd]
Decrease [qlco]
Lp(a) [aapp, bacs]
Plasminogen Activator Inhibitor 1 [aapp, bacs]
Marker [clna]
Bone [bpoc]
turnover [qnco]
Changed [ftcn]
cee [orch]
Dosage [qnco]
Conclusions [idcn]
Six [qnco]
months [tmco]
treatment [ftcn]
mg day [qnco]
Conjugated estrogen [horm, phsu, strd]
Equine [mamm]
Total Cholesterol [lbpr]
Cholesterol, LDL [bacs, strd]
Causing [ftcn]
increases [ftcn]
Triglycerides [bacs, lipd]
Observed [ftcn]
High dose [qnco]
Low-Dose Treatment [resa]
Maximal [qlco]
Cholesterol, LDL [bacs, strd]
lowering [spco]
effects [qlco]
Hormone replacement therapy [topp]
Cholesterol, HDL [bacs, lipd]
Apolipoprotein A-1 [aapp, bacs]
Lipoprotein (a) [aapp, bacs]
Plasminogen Activator Inhibitor 1 [aapp, bacs]
Required [ftcn]
Medium [inpr]
Dose [qnco]
mg% [qnco]
Conjugated [spco]
Equine [mamm]
Oestrogens [horm, phsu, strd]
Needed [qlco]
Dose [qnco]
Conjugated oestrogens [horm, phsu, strd]
Equine [mamm]
Optimal [qlco]
CARDIOVASCULAR [bdsy]
Bone [bpoc]
turnover [qnco]
